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NEUROLOGIC COMPLICATIONS
AFTER HEART TRANSPLANTATION
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ABSTRACT - Objective: Neurologic complications are known as important cause of morbidity and mortality in
orthotopic heart transplantation. Our aim was to identify the frequency and outcome of neurologic
complications after heart transplantation in a prospective observational study. Method: From September 93
to September 99, as part of our routine heart transplantation protocol all patients with end-stage cardiac
failure were evaluated by the same neurologist before and at the time of any neurologic event (symptom or
complaint) after transplantation. Results: Out of 120 candidates evaluated, 62 were successfully transplanted
(53 male; median age 45.5 years, median follow-up 26.8 months). Fifteen patients (24%) had ischemic, 22
(35%) idiopathic, 24 (39%) Chagas’ disease and 1 (2%) had congenital cardiomyopathy. Neurologic
complications occurred in 19 patients (31%): tremor, severe headache, transient encephalopathy and seizures
related to drug toxicity or metabolic changes in 13; peripheral neuropathy in 4; and spinal cord compression
in two (metastatic prostate cancer and epidural abscess). No symptomatic postoperative stroke was observed.
Conclusions: Although frequent, neurologic complications were seldom related to persistent neurologic
disability or death. Most of the complications resulted from immunosuppression, however, CNS infection was
rare. The absence of symptomatic stroke in our series may be related to the lower frequency of ischemic
cardiomyopathy.
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Complicações neurológicas em transplantes cardíacos
RESUMO - Objetivo: Complicações neurológicas são frequentemente descritas como causa de morbidade e
mortalidade em transplantes cardíacos. Nosso objetivo foi avaliar a frequência de complicações neurológicas
em pacientes submetidos a transplantes cardíacos, bem como sua evolução, através de um estudo prospectivo
observacional. Método: Todos os candidatos a transplantes cardíacos foram avaliados pelo mesmo neurologista,
como parte do protocolo de rotina de avaliação pré-transplante no período de 9/93 a 9/99. Após a cirurgia, os
pacientes foram reavaliados sempre que houvesse qualquer sintoma ou queixa neurológica. Resultados: Entre
120 pacientes avaliados no período pré-operatório, 62 foram transplantados (53 sexo masculino; idade mediana
de 45.5 anos; tempo de seguimento mediano 26.8 meses). A etiologia da miocardiopatia foi isquêmica em 15
pacientes (24%), idiopática em 22 (35%), chagásica em 24 (39%) e congênita em 1 (2%). Complicações
neurológicas ocorreram em 19 pacientes (31%): tremor, cefaléia intensa, encefalopatia transitória ou crises
relacionados com toxicidade medicamentosa ou alterações metabólicas em 13; neuropatia periférica em 4;
compressão medular em 2 (metástase epidural de carcinoma de próstata e abscesso epidural). Nenhum paciente
apresentou acidente vascular cerebral (AVC) sintomático no período pós-operatório. Conclusões: Apesar de
frequentes, as complicações neurológicas raramente provocaram seqüelas permanentes ou óbito. A maior
parte das complicações foi relacionada com imunossupressão, entretanto, infecções foram raras. A ausência
de pacientes com AVC sintomático pode estar associada com a baixa frequência de miocardiopatia isquêmica
na presente série.
PALAVRAS-CHAVE: transplante cardíaco, complicações pós-operatórias, doença de Chagas, miocardiopatia,
transtornos cerebrovasculares.
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Neurologic complications are known to be an
important cause of morbidity and mortality in other-
wise successful heart transplantation. Those compli-
cations have been described in up to 94% of pati-
ents, but some series are based on autopsy findings
and therefore may be potentially biased1-4. The most
common neuropathologic findings described in these
series are cerebrovascular events and central nervous
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system (CNS) opportunistic infections. However, most
of the autopsy studies were published in the 1970s
and 80s and, since then, many improvements in sur-
gical techniques as well as immunosuppression have
led to increasing survival rates and probably also to
changes in the nature, frequency and outcome of
the complications observed. Clinical studies have des-
cribed far fewer neurologic complications in those
patients; however, being retrospective, based on
chart reviews and autopsy findings, they may have
underestimated the frequency of the complications
reported5-10.
There are some recent clinical retrospective se-
ries in the pediatric population11-13, that are not com-
parable, considering that children have distinct car-
diomyopathies and risk factors.
As far as we know, the only prospective study in
adult patients addressed exclusively the cerebrovas-
cular complications of heart transplantation14.
The aim of our study was to identify the frequency
and outcome of neurologic complications in a pro-
spective observational study in our University Hos-
pital.
METHODS
From September 1993 to September 1999, as part of
our routine heart transplant protocol approved by the lo-
cal ethics committee, all patients over 15 years of age with
end-stage cardiac failure were evaluated by the same neu-
rologist, preoperatively and, after the operation, at the
time of any neurological event as detected by the trans-
plant team. Patients were subjected to a detailed preop-
erative neurologic examination and, after the operation
all patients with neurologic symptom or complaint were
reexamined. Whenever indicated, cranial CT and/or MRI,
CSF examination and electrophysiologic studies were per-
formed.
Primary cardiac diseases included ischemic, idiopathic
and congenital cardiomyopathy and also Chagas’ disease,
a very prevalent disease in Brazil15.
Transplant protocol
Exclusion criteria included present infection, neoplasm,
renal, hepatic or pulmonary failure, pulmonary hyperten-
sion and dementia or psychiatric illness.
Orthotopic heart transplantations were performed
under cardiopulmonary bypass with moderate hypother-
mia (28oC), non-pulsatile flow, membrane oxygenators,
and alpha-stat management. Prophylactic antibiotic
(cefazolin) was used in all patients.
The immunosuppressive protocol consisted of: 1) me-
thylprednisolone 500 mg before the end of bypass and
700 mg to 1 g IV from the first to the third postoperative
day, followed by oral prednisone 0.8 to 1.0 mg/kg/day,
progressively reduced to 0.15 to 0.2 mg/kg/day; 2) cy-
closporine 5 to 6 mg/kg/day beginning on the fourth post-
operative day, with doses adjusted to maintain blood lev-
els of 200 µg/dl; 3) azathioprine 4 mg/kg/day immediately
before the operation and 2.0 to 2.5 mg/kg/day as of the
first postoperative day.
Endomyocardial biopsy was performed weekly in the
first postoperative month, twice in the second month,
monthly until the sixth month, and whenever necessary
thereafter. In Chagas’ patients biopsies were also stained
with Giemsa and immunohistochemistry to T. cruzi.
Only greater than grade II (ISHLT) rejection16 episodes
were treated with boluses of IV methylprednisolone fol-
lowed by oral prednisone.
In Chagas’ patients prednisone was withdrawn in the
third postoperative month in order to minimize the risk of
reactivation due to immunosuppression and none of them
received prophylaxis to T. cruzi infection reactivation. Di-
agnosis of clinical Chagas’ disease reactivation was based
on detection of T. cruzi in blood samples (xenodiagnosis
and culture) and tissue biopsies. Whenever confirmed, all
reactivations were treated with allopurinol 600 to 900 mg/
kg/day during 60 days17,18.
Statistical analysis
Demographics and risk factors for cerebrovascular dis-
eases were compared for patients with and without neu-
rologic complications using Mann-Whitney U test for con-
tinuous variables and Fisher’s exact test for categorical
and dichotomous variables. For all tests, statistical signifi-
cance was accepted at p < 0.05.
RESULTS
Out of 120 candidates evaluated, 62 were suc-
cessfully transplanted. There were 53 men (85%) with
a median age of 45.5 years (ranging from 16 to 68
years). The median follow-up was 26.8 months (rang-
ing from 0.3 to 70.6+ months).
The prevailing etiology of cardiomyopathy was
Chagas’ disease in 24 patients (39%); 22 patients
(35%) had idiopathic cardiomyopathy, 15 (24%) had
ischemic cardiomyopathy, and only one (2%) patient
had congenital cardiomyopathy (transposition of
great arteries).
Table 1 shows demographic features and risk fac-
tors for cerebrovascular diseases in Chagas’, idio-
pathic (including in this group the only patient with
congenital cardiomyopathy) and ischemic patients.
Preoperative evaluation revealed three patients
(2 ischemic, 1 idiopathic) with previous strokes with
mild motor deficits, one (Chagas’) with previous TIA
and two diabetic patients (1 ischemic and 1 idio-
pathic) with mild peripheral neuropathy.
Neurologic complications occurred in 19 patients
(31%) (Table 2). Transient encephalopathy and/or sei-
zures were observed in 11 patients (3 Chagas’; 5 id-
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iopathic and 3 ischemic). All of them had normal
brain CT or MRI as well as CSF examinations. Severe
headache occurred in one Chagas’ patient, while one
ischemic patient presented with tremor. None of
these 13 episodes could be explained by infections
or cerebrovascular events and they were thought to
be related to documented metabolic changes (in 2
patients) or to drug toxicity (in 11), including cyclos-
porine (in 8), imipenem (in 2) and steroids (in 1), as
suggested by spontaneous improvement and com-
plete recovery after drug taper. Cyclosporine serum
levels were within or just above therapeutic range
in all patients. Long term antiepileptic drugs were
not used and only one patient had persistent atten-
tion and memory deficits.
Acute peripheral neuropathy (1 ulnar and 3 pero-
neal) in the immediate postoperative period occurred
in four patients (3 Chagas’ and 1 ischemic). All of
them had complete recovery within two months.
These events were probably related to compression
due to intraoperative positioning.
Spinal cord compression was observed in two is-
chemic patients, one caused by metastatic prostate
cancer with recovery after treatment and one with
epidural abscess (S. aureus) evolving to sepsis and
death, despite early surgical decompression com-
bined with antibiotics.
Only one patient with neurologic complication
died: the patient with spinal epidural abscess com-
plicated with sepsis.
With the exception of the spinal cord compres-
sions (29 and 36 months after transplantation in two
patients), all the remaining complications occurred
within the first two months after transplantation.
Neurologic complications could not be related to
demographic features and risk factors for cerebrovas-
Table 2. Neurologic complications after heart transplantation.
Neurologic complication Chagas’ Idiopathic Ischemic Congenital Total
n=24 n=22 n=15 n=1 n=62
Drug toxicity or metabolic 4 (17%) 5 (23%) 4 (27%) 0 13
Seizures and/or encephalopathy 3 5 3 0 11
Severe headache 1 0 0 0 1
Tremor 0 0 1 0 1
Peripheral neuropathy 3 (12%) 0 1 (7%) 0 4
Ulnar 1 0 0 0 1
Peroneal 2 0 1 0 3
Spinal cord compression 0 0 2 (13%) 0 2
Metastatic prostate cancer 0 0 1 0 1
Epidural spinal abscess 0 0 1 0 1
Total 7 (29%) 5 (23%) 7 (47%) 0 19 (31%)
Table 1. Demographics and risk factors for cerebrovascular disease in heart transplant recipients.
Chagas’ cardiomyopathy Idiopathic* cardiomyopathy Ischemic cardiomyopathy
n=24 n=23 n=15
Demographics
Median age (years) 37 50 54
Male 71% 91% 100%
Risk factors
Previous MI 0 0 87%
Arterial hypertension 0 0 40%
Smoking 38% 56% 80%
Hypercholesterolemia 8% 17% 27%
Previous stroke or TIA 4% 4% 13%
Diabetes 0 17% 7%
Alcoholic beverage 42% 30% 47%
*includes one patient with congenital cardiomyopathy
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cular diseases, including previous neurologic abnor-
malities (Table 3).
There are two noteworthy observations in our
series: no symptomatic postoperative stroke was ob-
served and none of the 7 Chagas’ patients with sys-
temic T. cruzi reactivation had CNS involvement.
DISCUSSION
Heart transplantation has become a definitive the-
rapeutic option for patients with end-stage cardiac
failure, with increasing survival rates after recent ad-
vances in surgical techniques and immunosuppres-
sion. Neurologic complications, however, are still
described as a frequent cause of morbidity and mor-
tality in these patients. Since most of the previous
studies are based on autopsy findings or retrospec-
tive reviews we conducted a prospective observa-
tional study to identify the frequency and outcome
of neurologic complications after heart transplanta-
tion in our university based hospital.
Of 120 candidates examined preoperatively 62
(52%) were transplanted in a 6-year study period.
Between 1984 and 1993, 380 heart transplantations
were performed in our country by 20 institutions,
including ours19. These numbers confirm that despite
the efforts of educational programs for the popula-
tion, the activity of transplantation programs in Bra-
zil, as in many other countries, is still severely lim-
ited by the availability of donor organs.
Drug related neurotoxicity was the most common
neurologic complication in our series (21%). Eleven
of our patients presented with seizures, sometimes
accompanied by transient encephalopathy, one pa-
tient presented with headache and another patient
with tremor. Seizures were seldom recurrent and no
patient received long-term antiepileptic drugs, as
described before20,21. Cyclosporine-associated neu-
rotoxicity, is a well known complication in liver, kid-
ney, bone marrow and heart transplantations. The
spectrum of clinical presentation includes seizures,
altered mental status with confusion, hallucinations,
tremor, headache, encephalopathy, cortical blindness
and coma, sometimes in combination20,22,23. The fre-
quency of these complications ranges from 10 to 40%
with a peak in the early postoperative period20,22,23
and most of the patients present reversible and re-
current symptoms or signs related to drug discon-
tinuation and reintroduction. Symptoms may occur
in the absence of documented high cyclosporine lev-
els24, as observed in our patients and the diagnosis
is usually one of exclusion22, often requiring normal
CT scan or MRI and lumbar puncture to rule out in-
fection or cerebrovascular events. The concomitant
use of other drugs such as steroids and imipenem
or the presence of metabolic changes, as observed
in 5 of our patients, can mimic cyclosporine-associ-
ated neurotoxicity symptoms.
Postoperative acute peripheral neuropathy occur-
red in 6% of our patients, probably related to intra-
operative positioning, and with a benign prognosis.
The frequency of this finding in heart transplanta-
tion is thought to be similar to that described after
open-heart surgery21,25,26. We observed a trend to
higher frequency of peripheral neuropathy in Chagas’
patients. Nascimento and coworkers27 described a
patient with chronic inflammatory neuropathy prob-
ably related to Chagas’ disease, and postulated an
immune delayed hypersensitivity mechanism to ex-
plain this finding. One might suppose that subclini-
cal preexistent neuropathy may have predisposed
Chagas’ patients to the acute neuropathy observed.
However, the two diabetic patients with mild signs
of peripheral neuropathy in the preoperative exami-
nation did not present new symptoms or worsening
of prior symptoms suggestive of acute peripheral
nerve lesions in the postoperative period.
Except for a possible susceptibility to peripheral
neuropathy, neurologic complications detected in the
present study were similar in Chagas’ and non-Cha-
gas’ patients, and could not be specifically related
to Chagas’ disease, as described before28. Chagas’
patients have not been included in the previous se-
Table 3. Neurologic complications related to demographic fea-
tures and risk factors for cerebrovascular diseases.
Complication Complication
present absent
n=19 n=43 p
Demographics
Median age (years) 46 45 0.21
Male 89% 34% 0.43
Risk factors
Arterial hypertension 16% 8% 0.26
Diabetes 0 13% 0.14
Hypercholesterolemia 21% 16% 0.36
Smoking 53% 59% 0.51
Alcoholic beverage 37% 40% 0.53
Previous stroke or TIA 0 11% 0.22
Previous MI 31% 19% 0.15
Previous neurologic
abnormalities 0 13% 0.14
p Fisher’s exact test except where indicated; 1 Mann-Whitney U test.
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ries that addressed the neurologic complications of
transplantation1-10,14 and one might suppose that they
could be at a higher risk of complications due to
immunosuppression. Reactivation of Chagas’ disease
with CNS involvement has been described in kidney
transplantation, leukemia and HIV patients29-35. Seven
of our patients presented cutaneous and myocar-
dial reactivation but none of them had neurologic
symptoms. Early prednisone withdrawn in Chagas’
patients may contribute to a reduction of systemic
reactivation observed after heart transplantation as
described before36,37. However, the absence of CNS
involvement in our seven patients with systemic re-
activation deserves further elucidation.
Spinal epidural empyema occurred in one ische-
mic patient. Although described in renal38,39 and li-
ver40 transplant recipients, this complication is rare
and as far as we know has not been previously de-
scribed in heart transplant recipients.
The absence of symptomatic postoperative stro-
kes in our patients is intriguing. Although most re-
cent cerebral infarcts are symptomatic, some silent
perioperative events may have been underestimated
in our patients due to methodological limitations.
However, infarctions observed in previous autopsy
and clinical retrospective series may also be overes-
timated considering that they may represent silent
preoperative events. Moreover, some series included
50 to 67% of patients with ischemic cardiomyopa-
thy5,8,14, that may present previous atherosclerotic
disease; one can speculate that cerebrovascular dis-
ease may antedate heart transplantation in those
patients, as suggested by Adair and coworkers14.
Recently, Jarquin-Valdivia and coworkers9 reported
an increase in ischemic stroke in patients with di-
lated cardiomyopathy among their series, which they
attribute to heart and aortic manipulation. However,
these risk factors are expected to be similar or even
higher in patients with ischemic cardiomyopathy, and
the authors comment that this finding may have to
be interpreted with caution. A future prospective stu-
dy including routine pre- and postoperative evalua-
tion with new MRI techniques may help to elucidate
this question.
Apart from the sample size that might explain at
least part of the negative results in the statistical ana-
lysis, the present study may have underestimated
the neurologic complications observed due to meth-
odological limitations: although all patients were
examined by the same neurologist before transplan-
tation, neurologic events were determined by the
transplant team in the postoperative period. There-
fore only the cases referred for consultation were
examined, which could have resulted in low sensitivi-
ty of detection in patients with minor deficits. The
transplant team, however, was the same through-
out the study period and a very close relationship
between the members of the team ensured prompt
evaluation of any patient with neurologic symptoms.
In conclusion, neurologic complications occurred
in 31% of our patients. Although frequent, those
complications were seldom related to persistent neu-
rologic disability or death. Most of the complications
resulted from immunosuppression (predominantly
cyclosporine toxicity); however, CNS infection was
rare, even in patients with Chagas’ disease who could
be potentially at a higher risk of T. cruzi reactivation.
The absence of strokes in our series may be related
to the lower frequency of ischemic cardiomyopathy.
This observation may contribute to the hypothesis
that strokes are primarily associated with previous
atherosclerotic cardiovascular disease rather than
with the surgery itself.
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